IBDEI1MF ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.4)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.4,1123,0)
 ;;=QUALIFYING CIRCUMSTANCES^16^86
 ;;^UTILITY(U,$J,358.4,1124,0)
 ;;=TEAM CONFERENCE^21^86
 ;;^UTILITY(U,$J,358.4,1125,0)
 ;;=COVID-19 CONFIRMED^2^87
 ;;^UTILITY(U,$J,358.4,1126,0)
 ;;=COVID-19 EXPOSURE^3^87
 ;;^UTILITY(U,$J,358.4,1127,0)
 ;;=COVID-19 RELATED COND/SYMP^5^87
 ;;^UTILITY(U,$J,358.4,1128,0)
 ;;=COVID-19 SCREEN^1^87
 ;;^UTILITY(U,$J,358.4,1129,0)
 ;;=COVID-19 PRE-OP^4^87
 ;;^UTILITY(U,$J,358.4,1130,0)
 ;;=COVID-19 ^1^88
 ;;^UTILITY(U,$J,358.4,1131,0)
 ;;=COVID-19 CONFIRMED^2^89
 ;;^UTILITY(U,$J,358.4,1132,0)
 ;;=COVID-19 EXPOSURE^3^89
 ;;^UTILITY(U,$J,358.4,1133,0)
 ;;=COVID-19 RELATED COND/SYMP^5^89
 ;;^UTILITY(U,$J,358.4,1134,0)
 ;;=COVID-19 SCREEN^1^89
 ;;^UTILITY(U,$J,358.4,1135,0)
 ;;=COVID-19 PRE-OP^4^89
 ;;^UTILITY(U,$J,358.4,1136,0)
 ;;=ESTABLISHED PATIENT^1^90
 ;;^UTILITY(U,$J,358.4,1137,0)
 ;;=GROUP PSYCHOTHERAPY/INTERVENTION^2^91
 ;;^UTILITY(U,$J,358.4,1138,0)
 ;;=OTHER^10^91
 ;;^UTILITY(U,$J,358.4,1139,0)
 ;;=TEAM CONFERENCE^9^91
 ;;^UTILITY(U,$J,358.4,1140,0)
 ;;=SUBSTANCE ABUSE^8^91
 ;;^UTILITY(U,$J,358.4,1141,0)
 ;;=CASE MANAGEMENT^1^91
 ;;^UTILITY(U,$J,358.4,1142,0)
 ;;=INJECTION ADMINISTRATION^6^91
 ;;^UTILITY(U,$J,358.4,1143,0)
 ;;=INJECTIONS/MEDICATIONS^7^91
 ;;^UTILITY(U,$J,358.4,1144,0)
 ;;=IN-HOME BEHAVIOR/HEALTH ASSESSMENT^5^91
 ;;^UTILITY(U,$J,358.4,1145,0)
 ;;=IMMUNIZATION ADMINISTRATION ^3^91
 ;;^UTILITY(U,$J,358.4,1146,0)
 ;;=IMMUNIZATIONS^4^91
 ;;^UTILITY(U,$J,358.4,1147,0)
 ;;=ABUSE,NEGLECT, & VIOLENCE^1^92
 ;;^UTILITY(U,$J,358.4,1148,0)
 ;;=ANXIETY DISORDERS^2^92
 ;;^UTILITY(U,$J,358.4,1149,0)
 ;;=BIPOLAR & RELATED DISORDERS^3^92
 ;;^UTILITY(U,$J,358.4,1150,0)
 ;;=NEUROCOGNITIVE DISORDERS^18^92
 ;;^UTILITY(U,$J,358.4,1151,0)
 ;;=DEPRESSIVE DISORDERS^8^92
 ;;^UTILITY(U,$J,358.4,1152,0)
 ;;=DISSOCIATIVE DISORDERS ^10^92
 ;;^UTILITY(U,$J,358.4,1153,0)
 ;;=FEEDING & EATING DISORDERS^13^92
 ;;^UTILITY(U,$J,358.4,1154,0)
 ;;=EDUC/OCCUPATIONAL PROBLEMS^11^92
 ;;^UTILITY(U,$J,358.4,1155,0)
 ;;=GENDER DYSPHORIA^15^92
 ;;^UTILITY(U,$J,358.4,1156,0)
 ;;=HOUSING/ECONOMIC PROBLEMS^16^92
 ;;^UTILITY(U,$J,358.4,1157,0)
 ;;=MEDICATION ADVERSE EFFECTS^17^92
 ;;^UTILITY(U,$J,358.4,1158,0)
 ;;=OBSESSIVE-COMPULSIVE & RELATED DISORDERS^20^92
 ;;^UTILITY(U,$J,358.4,1159,0)
 ;;=PERSONAL HX & CURRENT CIRCUMSTANCES^23^92
 ;;^UTILITY(U,$J,358.4,1160,0)
 ;;=COUNSELING/MEDICAL ADVICE^5^92
 ;;^UTILITY(U,$J,358.4,1161,0)
 ;;=SOCIAL ENVIRONMENT PROBLEMS^30^92
 ;;^UTILITY(U,$J,358.4,1162,0)
 ;;=PARAPHILIC DISORDERS^22^92
 ;;^UTILITY(U,$J,358.4,1163,0)
 ;;=PERSONALITY DISORDERS^24^92
 ;;^UTILITY(U,$J,358.4,1164,0)
 ;;=CRIME/LEGAL SYSTEM PROBLEMS^6^92
 ;;^UTILITY(U,$J,358.4,1165,0)
 ;;=PSYCHOSOCIAL/PERSONAL/ENVIRONMENTAL^25^92
 ;;^UTILITY(U,$J,358.4,1166,0)
 ;;=RELATIONAL PROBLEMS^26^92
 ;;^UTILITY(U,$J,358.4,1167,0)
 ;;=SCHIZOPHRENIA/OTH PSYCHOTIC DISORDERS^27^92
 ;;^UTILITY(U,$J,358.4,1168,0)
 ;;=SEXUAL DYSFUNCTIONS^28^92
 ;;^UTILITY(U,$J,358.4,1169,0)
 ;;=SLEEP-WAKE DISORDERS^29^92
 ;;^UTILITY(U,$J,358.4,1170,0)
 ;;=SUBSTANCE DISORDER-ALCOHOL^32^92
 ;;^UTILITY(U,$J,358.4,1171,0)
 ;;=SUBSTANCE DISORDER-CANNABIS^34^92
 ;;^UTILITY(U,$J,358.4,1172,0)
 ;;=SUBSTANCE DISORDER-HALLUCINOGEN^35^92
 ;;^UTILITY(U,$J,358.4,1173,0)
 ;;=SUBSTANCE DISORDER-OPIOID^37^92
 ;;^UTILITY(U,$J,358.4,1174,0)
 ;;=SUBSTANCE DISORDER-SEDATIVE/HYPNOTIC^38^92
 ;;^UTILITY(U,$J,358.4,1175,0)
 ;;=SUBSTANCE DISORDER-TOBACCO^40^92
